Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Michael

Showing results (71-80 of 216) with videos related to

Pageof 22
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 6, 2023
Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacistsSarah Glewis, Senthil Lingaratnam, Mei Krishnasamy, et al.
Clinical Colorectal Cancer|January 24, 2007
Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil countMichael Michael, David Goldstein, Stephen J Clarke, et al.
Acta Oncologica (Stockholm, Sweden)|April 1, 2003
FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burdenMichael R MacManus, Rodney Hicks, Richard Fisher, et al.
The Oncologist|February 22, 2017
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic ReviewMichael Michael, Rocio Garcia-Carbonero, Matthias M Weber, et al.
Internal Medicine Journal|May 20, 2024
Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologistsAlexandra Flynn, Peter Galettis, Howard Gurney, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 16, 2013
Understanding how cancer patients actualise, relinquish, and reject advance care planning: implications for practiceNatasha Michael, Clare O'Callaghan, Josephine Clayton, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape|March 5, 2009
Fixation-off sensitivity in epilepsies other than the idiopathic epilepsies of childhood with occipital paroxysms: a 12-year clinical-video EEG studyMichail Koutroumanidis, Katerina Tsatsou, Sue Sanders, et al.
ANZ Journal of Surgery|December 17, 2022
Appendiceal pseudomyxoma peritonei: unmasking the indolent invaderAnshini Jain, Michael P Flood, Robert Ramsay, et al.
Clinical Colorectal Cancer|August 8, 2007
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacyStephen Clarke, David Goldstein, Paul Mitchell, et al.
Endocrine Oncology (Bristol, England)|July 23, 2025
Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumoursIsuru Gamage, Emma Boehm, Gaurav Ghosh, et al.
Pageof 22

Showing results (71-80 of 216) with videos related to

Sort By:
Pageof 22
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 6, 2023
Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacistsSarah Glewis, Senthil Lingaratnam, Mei Krishnasamy, et al.
Clinical Colorectal Cancer|January 24, 2007
Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil countMichael Michael, David Goldstein, Stephen J Clarke, et al.
Acta Oncologica (Stockholm, Sweden)|April 1, 2003
FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burdenMichael R MacManus, Rodney Hicks, Richard Fisher, et al.
The Oncologist|February 22, 2017
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic ReviewMichael Michael, Rocio Garcia-Carbonero, Matthias M Weber, et al.
Internal Medicine Journal|May 20, 2024
Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologistsAlexandra Flynn, Peter Galettis, Howard Gurney, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 16, 2013
Understanding how cancer patients actualise, relinquish, and reject advance care planning: implications for practiceNatasha Michael, Clare O'Callaghan, Josephine Clayton, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape|March 5, 2009
Fixation-off sensitivity in epilepsies other than the idiopathic epilepsies of childhood with occipital paroxysms: a 12-year clinical-video EEG studyMichail Koutroumanidis, Katerina Tsatsou, Sue Sanders, et al.
ANZ Journal of Surgery|December 17, 2022
Appendiceal pseudomyxoma peritonei: unmasking the indolent invaderAnshini Jain, Michael P Flood, Robert Ramsay, et al.
Clinical Colorectal Cancer|August 8, 2007
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacyStephen Clarke, David Goldstein, Paul Mitchell, et al.
Endocrine Oncology (Bristol, England)|July 23, 2025
Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumoursIsuru Gamage, Emma Boehm, Gaurav Ghosh, et al.
Pageof 22